SAN FRANCISCO — In this Healio Video Perspective from the AAO meeting, Benjamin Xu, MD, reports similar outcomes for patients using Dextenza compared with more conventional treatments after cataract surgery.
Using real-world data from the IRIS Registry, Xu and colleagues compared safety outcomes of patients who received Dextenza (dexamethasone ophthalmic insert 0.4 mg, Ocular Therapeutix) vs. a normal steroid regimen after cataract surgery.
“Both methods provided similar amounts of inflammation control, which was very minimal, especially after the first day,” Xu said. Steroid